Expert Ratings For Pacira BioSciences
Portfolio Pulse from Benzinga Insights
Pacira BioSciences (NASDAQ:PCRX) has received mixed analyst ratings, with a notable decrease in the average 12-month price target from $41.29 to $30.36. Analysts have adjusted their ratings and price targets, reflecting varied expectations for the company's future performance. Despite a strong net margin and effective debt management, Pacira's revenue growth lags behind industry peers.
September 24, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Pacira BioSciences has received a mix of bullish and bearish analyst ratings, with a significant drop in the average 12-month price target. Analysts have adjusted their ratings and price targets, indicating varied expectations for the company's future performance. Despite strong financial metrics like net margin and debt management, the company's revenue growth is slower than its peers.
The significant drop in the average price target from $41.29 to $30.36 suggests a bearish outlook from analysts. The mixed ratings, with several analysts lowering their price targets, indicate concerns about the company's future performance. Despite strong financial metrics, the slower revenue growth compared to peers may contribute to the negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100